MassBiologics; Department of Obstetrics and Gynecology; Department of Pediatrics, Division of Immunology and Infectious Disease; Department of Biochemistry and Molecular Pharmacology
Female Urogenital Diseases and Pregnancy Complications | Maternal and Child Health | Obstetrics and Gynecology | Women's Health
Angiogenic biomarkers, including soluble fms-like tyrosine kinase 1 (sFlt1), are thought to be predictors of preeclampsia onset; however, improvement is needed before a widespread diagnostic test can be utilized. Here we describe the development and use of diagnostic monoclonal antibodies specific to the two main splice variants of sFlt1, sFlt1-1 and sFlt1-14. These antibodies were selected for their sensitivity and specificity to their respective sFlt1 isoform in a capture ELISA format. Data from this pilot study suggest that sFlt1-1 may be more predictive of preeclampsia than total sFlt1. It may be possible to improve current diagnostic platforms if more specific antibodies are utilized.
Rights and Permissions
Citation: Int J Mol Sci. 2015 Jun 2;16(6):12436-53. doi: 10.3390/ijms160612436. Link to article on publisher's site
diagnostic, isoforms, monoclonal antibody (mAb), preeclampsia, soluble fms-like tyrosine kinase 1 (sFlt1), splice variants
Souders, Colby A.; Maynard, Sharon E.; Yan, Jing; Wang, Yan; Boatright, Naomi; Sedan, Jessica; Balyozian, David; Cheslock, Peter S.; Molrine, Deborah C.; and Moore Simas, Tiffany A., "Circulating Levels of sFlt1 Splice Variants as Predictive Markers for the Development of Preeclampsia" (2015). Obstetrics and Gynecology Publications and Presentations. 108.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.